HIV (last infection disease section) Flashcards
OraQuick
in-home HIV test, OTC
use after 3 months of exposure… minimum
stage 1: bindin/attachment
HIV attaches to a CD4 receptor and CCR5 and/or CXCR4.
CCR5 antagonist: Maraviroc
attachment inhibitor: fostemsavir
post-attachment inhibitor:
ibalizumab-uiyk
stage 2: fusion
HIV viral envelope fuses with he CD4 cell membrane. HIV enters the host cell and releases HIV RNA, viral proteins and enzyme needed for replication
Fusion inhibitor: enfuvirtide
stage 3: Reverse Transcription
HIV RNA is conveted to the HIV DNA by reverse transcriptase.. HIV DNA can enter the CD4 cell nucleus
nucleoside reverse transcriptase inhibitors (NRTIs): emtricitabine, tenofovir, etc.
non-nucleoside reverse transcriptase inhibitors (NNRTIs): efavirenz, rilpivirine, etc.
stage 4: integration
once inside the CD4 cell nucleus integrase is released and used to insert HIV DNA into the host cell DNA
integrase strand transfer inhibitors (INSTIs): bictegravir, dolutegravir, raltegravir
stage 5: replication
host ell machinery is used to transcribe and translate HIV DNA into HIV RNA
no med
stage 6: assembly
New HIV RNA assembled into a immature HIV
no med
Stage 7: budding and maturation
immature HIV pushes out of the CD4 and protease breaks up the long viral protein chain creating mature virus that can infect other cells
protease inhibitors: atazanavir, darunavir
Biktarvy
Bictegravir/ Emtricitabine/ Tenofovir alafenamide
one pill daily
Triumeq
Dolutegravir/ Abacavir/ Lamivudine
one pill daily
Dovato
Dolutegravir/ Lamivudine
one pill daily
Tivicay +
Truvada
Dolutegravir +
Emtricitabine/ Tenofovir disoproxil fumarate
Tivicay +
Descovy
Dolutegravir +
Emtricitabine/ Tenofovir alafenamide
Most preferred regiments contain
2 NRTIs 1 INSTI
Truvada or Descovy make up the NRTI backbone in most regiments
Lamivudine and emtricitabine are interchangeable but should not be used together
Davato (1 NRTI and 1 INSTI)
an exception to above
- do not use in tx naive pt if HIV RNA >500,000 copies/ml,
- there is a known hep B co-infection (or status unknown)
- or HIV genotypic test is not yet available
Trimeq contains abacavir
extra testing is required
test for HLA-B*5701 allele before using. A positive result indicates a higher risk for a severe hypersensitivity reaction (HSR) and any abacavir- containing product is contraindicted
Fixed- dose
combo have less flexibility with renal dosing
Biktarvy, triumeq, dovato, truvada, descovy: do not use if CrCl <30 ml/min
except for biktarvy, individuals components of these drugs can be given separately to allow for more flexible renal dose adjustment
Alternative ART regiments
one “base” plus two NRTs to serve as the “backbone”
the “base” can be, PI, an NNRTI, or an INSTI
Alternative ART regiment
PI-based (boosted w/cobicistat or ritonavir)
Darunavir or atazanavir
Alternative ART regiments
NNRTI-based
Efavirenz or rilpivirine
Alternative ART regiments
INSTI-based
Elvitegravir (only available in combo products)
Raltegravir
Alternative ART regiments
NRTI backbone?
TDF or TAF or abacavir PLUS
Emtricitabine or lamivudine
TDF= tenofovir disoproxil fumarate
TAF= tenofovir alafenamide
Alternative ART regiments
complete regimen examples
Rilpivirine + TDF + emtricitabine
Raltegravir + TAF + emtricitabine
abacavir
ziagen
screen for HLA-B*5701
pt must carry med card for HSR
never rechallenge pt w/ history of HSR
consider avoid in CVD pt due to increased risk of MI
all NRTIs except abacavir require renal dose adjustment
- NRTIs
Emtricitabine
Emtriva
hyperpigmentation of the palms of the hands and soles of the feet
- NRTIs
Lamivudine
Epivir
- NRTIs
Tenofovir alafenamide
TAF
only in combo products for HIV;
Vemlidy is a single-entity product for HBV
renal impairment, dose adjust with other renal toxic drugs,
can decrease bone mineral density consider calcium/vitamin D supplement and DEXA scan if at risk
monitor lipid if switching from TDF to TAF
- NRTIs
Zidovudine
Retrovir
hematologic toxic: neutropenia and anemia (increased MCV is a sign of adherence)
myopathy SE
- NRTIs
NRTIs general info
warning: lactic acidosis and hepatomegaly with steatosis (fatty liver)
SE: nausea, diarrhea, headache, increased LFTs
Severe acute HBV exacerbation can occur if emtricitabine, lamivudine, or tenofovir-containing products are D/C (some NRTs tx HBV)
do now use epivir-HBV to tx HIV (low dose of lamivudine)
Bictegravir
only in combo with Biktarvy
renal <30 ml/min do not start Biktarvy or Genvoya
increases SCr
- INSTIs
Dolutegravir
Tivicay
increases SCr
hypersensitivity reaction (HSR) w/ severe rash and organ dysfunction, including hepatotoxicity
small risk of neural tube defects in developing fetus (still preferred drug for HIV tx during prego)
increased CPK and myalgia
- INSTIs
Elvitegravir
only in combo, Genvoya and Stribild
CrCl< 70ml/min do not start Stribild
CrCl<50ml/min d/c Stribild
proteinuria
- INSTIs
Raltegravir
Isentress, Isentress HD
increased CPK, myopathy, and rhabdo
- INSTIs
All - INSTIs general
headache, insomnia, diarrhea, weight gain, rare risk of depression, and suicidal ideation in pt with pre-existing psychiatric condition (except bictegravir)
Take INSTIs 2hrs before or 6hrs after: aluminum, calcium, mag, or iron-containing products
Dolutegravir and bictegravir can be taken with oral calcium or iron if taken w/food
dose separation with raltegravir may not be effective, avoid polyvalent cations if possible
Efavirenz
Sustiva
- psychiatric symptoms (depression, suicidal thoughts)
- CNS effects (impaired concentration, abnormal dreams, confusion), generally resolve in 2-4 weeks
- increases total cholesterol and triglycerides
-NNRTIs
Rilpivirine
Edurant
- depression
- increased SCr w/ no effect on GFR
- do not use if viral load >100,000 copies/ml and/or CD4 count <200 cells (higher failure rate)
DO NOT USE WITH PPIs
Separate H2RAs at least 12hrs before or 4hrs after rilpivirine
-NNRTIs
Doravirine
Etravirine
Nevirapine
Pifeltro
Intelence
Viramune XR
-NNRTIs
NNRTIs general
hepatotoxicity and rash/severe rash, including SJS/TEN: highest risk with nevirapine
all NNRTIs major cyp3A4 substrate
Rilpivirine and doravirine: do not use with strong cyp3A4 inducer (carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine, st. john’s wort)
Doravirine
Etravirine
Nevirapine
Pifeltro
Intelence
Viramune XR
NNRTI
Atazanavir
Reyataz
hyperbilirubinemia (bananavir)
requires acid for absorption
- antacids 2hrs before or 1hr after
- H2RAs avoid or 2hrs before or 10 hrs after
- PPIs avoid with unboosted atazanavir, take boosted at least 12hrs after (do not exceed 20mg of omeprazole or equivalent)
- PIs
Darunavir
Prezista
sulfa allergy
- PIs
Fosamprenavir
Lexiva
sulfa allergy
- PIs
Lopinavir/ritonavir
Kaletra
ritonavir is a booster
oral solution contains 42% alcohol: can cause disulfiram reaction if taken with metronidazole
- PIs
Saquinavir
Invirase
- PIs
Tipranavir
Aptivus
sulfa allergy
intracranial hemorrhage
- PIs
PIs general
decrease HDL, increase LDL and TG
increase CVD
hepatic dysfunction
hypersensitivity reaction (SJS/TENS)
increase BG
insulin resistance
abdominal adiposity
PIs CYP
cyp3A4
do not use with:
- alfuzosin
- colchicine
- dronedarone
- lova and simva (rosuva and atorva preffered)
- inducers (carbamazepine, phenytoin, rifampin, st. john’s wort
- direct-acting antivirals for hep C
- hormonal contraceptives
- steroids
ritonavir
Norvir
with food, oral solution contains 43% alcohol
strong inhibitor of cyp3A4, cyp2D6, some OAT family and P-gp transporter
- boosters
cobicistat
tybost
with food
strong inhibitor of cyp3A4, cyp2D6, some OAT family and P-gp transporter
- boosters
Maraviroc
Selzentry
CCR5 antagonist
- Entry and attachment inhibitor
Fostemsavir
Rukovia
attachment inhibitor
- entry and attachment inhibitor
ibalizumab-uiyk
trogarzo- IV
post-attachment inhibitor
- entry and attachment inhibitor
Enfuvirtide
Fuzeion
fusion inhibitor
- entry and attachment inhibitor
bictegravir/ emtricitabine/ tenofovir alafenamide
biktarvy
- INSTI- based
Dolutegravir/ abacavir/ lamivudine
Triumeq
- INSTI- based
Dolutegravir/ lamivudine
Dovato
- INSTI- based
Elvitegravir/ clobistat/ emtricitabine/ tenofovir disoproxil fumarate
Stribild
- INSTI- based
Elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamide
Genvoya
- INSTI- based
Efavirenz/ emtricitabine/ tenofivr disoproxil fumarate
Atripla
- NNRTI- based
Rilpivirine/ emtricitabine/ tenofovir disoproxil fumarate
Complera
- NNRTI- based
Rilpivirine/ emtricitabine/ tenofovir alafenamide
Odefsey
Abacavir/ lamivudine
Epzicom
- NRTI combo
Emtricitabine/ tenofovir alafenamide
Descovy
- NRTI combo
Emtricitabine/ tenofovir disoproxil fumarate
Truvada
- NRTI combo
Prego NRTI combo
- abacavir/ lamivudine
- Tenofovir disoproxil fumarate/ emtricitabine
- tenofovir disoproxil fumarate/ lamivudine
prego INSTI
- raltegravir
- Dolutegravir
Boosted PI
- atazanavir+ ritonavir
- Darunavir + ritonavir
PrEP
before high-risk activity
1 oral drug taken daily, truvada or descovy
PEP
after HIV- exposure within 72 hrs taken for 28 days
Truvada (if CrCL >60) +
Dolutegravir (Tivicay) or
Raltegravir (Isentress)
prego and HIV
zidovudine to prevent HIV transmission to infant
- NRTI